[Preventive chemotherapy of duodenal ulcer]

An attempt was made to solve the problem in preventive drug therapy for duodenal ulcer in terms of various types of the course of the disease, its heterogeneity, features of metabolic processes, a patient's age, individual selection of the optimal drug, its dosage, regimen, intake duration, which would provide a differential individual design of drug therapy and change multicomponent drug therapy by mono- or diet therapy. Pharmacokinetic features of currently available antiulcer agents of groups of pyrenezepine or H2-blockers of histamine are presented, which should be taken into account when these drugs are used. A relationship is shown between the pharmacokinetics of drugs to an immune response as production of specific anti-drug++ antibodies that occasionally cause inefficiency of the therapy performed and a relapse of the disease during continuous treatment. The outcomes of differential preventive therapy are given in various types of the course of duodenal ulcer.